Get the Stockscreener App
11.65
1.60%
-0.19
After Hours:
11.97
0.32
+2.75%
Amylyx Pharmaceuticals Inc stock is traded at $11.65, with a volume of 2.08M.
It is down -1.60% in the last 24 hours and up +42.07% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$11.84
Open:
$11.84
24h Volume:
2.08M
Relative Volume:
1.25
Market Cap:
$1.04B
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-4.66
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
+14.22%
1M Performance:
+42.07%
6M Performance:
+197.95%
1Y Performance:
+367.87%
1-Day Range:
$11.44
$11.99
1-Week Range:
$10.07
$12.25
52-Week Range:
$2.48
$12.25
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
11.65 | 1.05B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals prices $175M public offering - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap UpWhat's Next? - MarketBeat
Amylyx announces proposed public offering of common stock - MSN
Alyeska Investment Group L.P. Decreases Holdings in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
American Century Companies Inc. Increases Position in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week HighHere's Why - MarketBeat
Adage Capital Partners GP L.L.C. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals Announces $164 Million Stock Offering - TipRanks
PMV to pursue FDA approval in ovarian cancer; Amylyx reveals $175M offering - Endpoints News
Amylyx Pharmaceuticals shares fall after $175 million follow-on offering By Investing.com - Investing.com Canada
Amylyx launches public offering of common stock By Investing.com - Investing.com Australia
Amylyx prices public offering of 17.5 million shares at $10 each - Investing.com Nigeria
Invesco Ltd. Invests $162,000 in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals announces pricing of $175 million underwritten public offering of common stock - MarketScreener
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Amylyx launches public offering of common stock - Investing.com India
Amylyx Pharmaceuticals at Baird Global Healthcare Conference: Advancing Rare Disease Treatments - Investing.com Canada
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
Amylyx Pharmaceuticals Launches Offering of Common Shares - MarketScreener
Amylyx Pharmaceuticals announces proposed public offering of common stock - MarketScreener
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Yahoo Finance
Market Outlook: Is Amylyx Pharmaceuticals Inc. a turnaround storyQuarterly Earnings Summary & AI Forecast for Swing Trade Picks - Lancaster City Council
266,099 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Allostery Investments LP - MarketBeat
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 04 - MarketScreener
Almitas Capital LLC Has $7.51 Million Holdings in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Hits New 12-Month HighWhat's Next? - MarketBeat
ADAR1 Capital Management LLC Buys 1,461,587 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Charles Schwab Investment Management Inc. Has $1.32 Million Holdings in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Understanding Amylyx Pharmaceuticals Inc.’s price movement2025 Market Overview & Reliable Volume Spike Alerts - Newser
Sector ETF performance correlation with Amylyx Pharmaceuticals Inc.July 2025 Fed Impact & Accurate Buy Signal Notifications - Newser
Will Amylyx Pharmaceuticals Inc. rebound enough to break evenProfit Target & Consistent Return Investment Signals - Newser
683 Capital Management LLC Increases Position in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Short interest data insights for Amylyx Pharmaceuticals Inc.2025 Major Catalysts & Fast Exit and Entry Strategy Plans - Newser
Market Catalysts: Will Amylyx Pharmaceuticals Inc. benefit from geopolitical trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - خودرو بانک
Amylyx Pharmaceuticals, Inc. $AMLX Stake Boosted by Nantahala Capital Management LLC - MarketBeat
Will Amylyx Pharmaceuticals Inc. benefit from current market trends2025 Fundamental Recap & Intraday High Probability Setup Alerts - خودرو بانک
Live market analysis of Amylyx Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Community Shared Stock Ideas - Newser
What high frequency data says about Amylyx Pharmaceuticals Inc.Market Sentiment Review & Daily Momentum Trading Reports - Newser
Can Amylyx Pharmaceuticals Inc. stock outperform in a bear marketJuly 2025 Weekly Recap & High Return Trade Guides - خودرو بانک
Is Amylyx Pharmaceuticals Inc. building a consolidation baseWeekly Risk Report & Trade Opportunity Analysis Reports - Newser
Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Walleye Capital LLC - MarketBeat
Is Amylyx Pharmaceuticals Inc. stock poised for growthWeekly Trend Report & Smart Swing Trading Alerts - Newser
Analyzing Amylyx Pharmaceuticals Inc. with multi timeframe charts2025 Stock Rankings & Safe Entry Trade Reports - Newser
What is Amylyx Pharmaceuticals Inc.’s TAM (Total Addressable Market)July 2025 Patterns & High Conviction Investment Ideas - خودرو بانک
Will Amylyx Pharmaceuticals Inc. outperform during market ralliesJuly 2025 Recap & Verified Momentum Stock Watchlist - خودرو بانک
Is Amylyx Pharmaceuticals Inc. showing insider buyingJuly 2025 Action & AI Optimized Trade Strategies - خودرو بانک
What data driven models say about Amylyx Pharmaceuticals Inc.’s futureWeekly Stock Analysis & Community Consensus Picks - Newser
Is Amylyx Pharmaceuticals Inc. stock a good pick for beginnersGDP Growth & Long-Term Safe Investment Ideas - خودرو بانک
Can technical indicators confirm Amylyx Pharmaceuticals Inc.’s reversalTrend Reversal & Low Risk Entry Point Guides - Newser
What to expect from Amylyx Pharmaceuticals Inc. in the next 30 daysStop Loss & Daily Stock Trend Reports - Newser
What’s next for Amylyx Pharmaceuticals Inc. stock priceAnalyst Upgrade & Momentum Based Trading Signals - Newser
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):